Repligen (RGEN) Research & Development (2010 - 2026)
Repligen (RGEN) posted quarterly Research & Development of $14.4 million for Q2 2026, up 3.2% year-over-year from $14.0 million in Q2 2025, and little changed quarter-over-quarter from $14.5 million in Q1 2026.
Repligen (RGEN) Research & Development (2010 - 2026) Analysis & Trends
Repligen (RGEN) has reported Research & Development for 17 consecutive years, with $14.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development rose 3.2% year-over-year to $14.4 million; the TTM figure through Jun 2026 stood at $56.2 million (up 18.32% YoY), while the FY2025 annual figure was $54.2 million, up 25.41% from the prior year.
- Research & Development was little changed at $14.4 million in Q2 2026 per RGEN's latest filing, from $14.5 million in the prior quarter.
- Across five years, Research & Development topped out at $14.5 million in Q1 2026 and bottomed at $9.7 million in Q2 2023.
- Historically, Research & Development has averaged $11.8 million across 5 years, with a median of $11.5 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development jumped 59.68% — and 2024, when it fell 8.2%.
- Repligen's Research & Development stood at $11.1 million in 2022, then declined by 7.45% to $10.3 million in 2023, then advanced by 13.53% to $11.7 million in 2024, then rose by 12.36% to $13.1 million in 2025, then advanced by 9.89% to $14.4 million in 2026.
- Business Quant data shows RGEN's Research & Development at $14.4 million in Q2 2026, $14.5 million in Q1 2026, and $13.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.22 Bn | 129.00 Bn | 1.96 Bn | 370.60 Mn |
| 2 | Becton Dickinson | 52.42 Bn | 51.56 Bn | 2.32 Bn | 258.00 Mn |
| 3 | Alcon | 35.74 Bn | 34.39 Bn | 1.68 Bn | 663.00 Mn |
| 4 | Resmed | 33.89 Bn | 32.42 Bn | 861.22 Mn | 105.73 Mn |
| 5 | Medline | 28.89 Bn | 26.21 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.07 Bn | 24.64 Bn | 329.20 Mn | 19.70 Mn |
| 7 | Solventum | 15.30 Bn | 14.90 Bn | 1.29 Bn | 178.00 Mn |
| 8 | Cooper Companies | 14.83 Bn | 14.69 Bn | 735.40 Mn | 42.50 Mn |
| 9 | Baxter International | 13.62 Bn | 11.47 Bn | 1.03 Bn | 129.00 Mn |
| 10 | Repligen | 10.13 Bn | 9.11 Bn | 110.04 Mn | 14.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.42 Mn |
| Mar 31, 2026 | 14.46 Mn |
| Dec 31, 2025 | 13.12 Mn |
| Sep 30, 2025 | 14.18 Mn |
| Jun 30, 2025 | 13.97 Mn |
| Mar 31, 2025 | 12.11 Mn |
| Dec 31, 2024 | 11.68 Mn |
| Sep 30, 2024 | 9.71 Mn |
| Jun 30, 2024 | 10.58 Mn |
| Mar 31, 2024 | 11.24 Mn |
| Dec 31, 2023 | 10.29 Mn |
| Sep 30, 2023 | 10.58 Mn |
| Jun 30, 2023 | 9.71 Mn |
| Mar 31, 2023 | 12.15 Mn |
| Dec 31, 2022 | 11.11 Mn |
| Sep 30, 2022 | 10.23 Mn |
| Jun 30, 2022 | 10.44 Mn |
| Mar 31, 2022 | 12.16 Mn |
| Dec 31, 2021 | 9.12 Mn |
| Sep 30, 2021 | 9.15 Mn |